

Loïc Guillevin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/699977/publications.pdf>

Version: 2024-02-01

344
papers

38,466
citations

2669

95
h-index

3021

188
g-index

388
all docs

388
docs citations

388
times ranked

14117
citing authors

#	ARTICLE	IF	CITATIONS
1	2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism, 2013, 65, 1-11.	6.7	4,839
2	Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis. Journal of the American Society of Nephrology: JASN, 2007, 18, 2180-2188.	3.0	973
3	EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 310-317.	0.5	889
4	Churg-Strauss Syndrome Clinical Study and Long-Term Follow-Up of 96 Patients. Medicine (United States), 1996, 75, 17-28.	0.4	887
5	Prognostic Factors in Polyarteritis Nodosa and Churg-Strauss Syndrome A Prospective Study in 342 Patients. Medicine (United States), 1996, 75, 17-28.	0.4	853
6	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. New England Journal of Medicine, 2014, 371, 1771-1780.	13.9	842
7	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	13.9	820
8	Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis and Rheumatism, 1999, 42, 421-430.	6.7	766
9	The Five-Factor Score Revisited. Medicine (United States), 2011, 90, 19-27.	0.4	716
10	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis and Rheumatism, 2013, 65, 270-281.	6.7	670
11	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis and Rheumatism, 2005, 52, 3792-3800.	6.7	656
12	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. New England Journal of Medicine, 2008, 359, 2790-2803.	13.9	603
13	EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 318-323.	0.5	596
14	Antineutrophil Cytoplasmic Antibodies and the Churg-Strauss Syndrome. Annals of Internal Medicine, 2005, 143, 632.	2.0	592
15	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.5	524
16	Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis and Rheumatism, 2001, 44, 666-675.	6.7	507
17	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis and Rheumatism, 2010, 62, 616-626.	6.7	483
18	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism, 2002, 46, 1309-1318.	6.7	480

#	ARTICLE	IF	CITATIONS
19	A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 1997, 40, 2187-2198.	6.7	475
20	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
21	Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture-recapture estimate. <i>Arthritis and Rheumatism</i> , 2004, 51, 92-99.	6.7	453
22	Hepatitis B Virus-Associated Polyarteritis Nodosa. <i>Medicine (United States)</i> , 2005, 84, 313-322.	0.4	371
23	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
24	Pulmonary Wegener's Granulomatosis. <i>Chest</i> , 1990, 97, 906-912.	0.4	358
25	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1004-1010.	0.5	343
26	Polyarteritis Nodosa Related to Hepatitis B Virus A Prospective Study with Long-Term Observation of 41 Patients. <i>Medicine (United States)</i> , 1995, 74, 238-253.	0.4	332
27	Presentation and Outcome of Gastrointestinal Involvement in Systemic Necrotizing Vasculitides. <i>Medicine (United States)</i> , 2005, 84, 115-128.	0.4	332
28	Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	3.5	302
29	Treatment of Churg-Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, open-label study of seventy-two patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 586-594.	6.7	294
30	Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. <i>British Journal of Rheumatology</i> , 2002, 41, 1126-1132.	2.5	276
31	Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 176-184.	1.4	276
32	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 351-357.	0.5	261
33	BSR and BHRP guidelines for the management of adults with ANCA associated vasculitis. <i>Rheumatology</i> , 2007, 46, 1615-1616.	0.9	259
34	Vasculitides associated with malignancies: Analysis of sixty patients. <i>Arthritis and Rheumatism</i> , 2007, 57, 1473-1480.	6.7	255
35	CLINICAL FINDINGS AND PROGNOSIS OF POLYARTERITIS NODOSA AND CHURG-STRAUSS ANGIITIS: A STUDY IN 165 PATIENTS. <i>Rheumatology</i> , 1988, 27, 258-264.	0.9	244
36	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007, 57, 686-693.	6.7	243

#	ARTICLE	IF	CITATIONS
37	Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. <i>Arthritis and Rheumatism</i> , 2008, 58, 2908-2918.	6.7	231
38	Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. <i>Arthritis and Rheumatism</i> , 2003, 49, 93-100.	6.7	225
39	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1143-1149.	0.5	219
40	Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. <i>Arthritis and Rheumatism</i> , 1995, 38, 1638-1645.	6.7	215
41	Microscopic Polyangiitis with Alveolar Hemorrhage A Study of 29 Cases and Review of the Literature. <i>Medicine (United States)</i> , 2000, 79, 222-233.	0.4	212
42	Deaths Occurring During the First Year After Treatment Onset for Polyarteritis Nodosa, Microscopic Polyangiitis, and Churg-Strauss Syndrome. <i>Medicine (United States)</i> , 2005, 84, 323-330.	0.4	210
43	Churg-Strauss syndrome. <i>Current Opinion in Rheumatology</i> , 2007, 19, 25-32.	2.0	199
44	Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 73.	0.7	198
45	The spectrum of vasculitis in human immunodeficiency virus-infected patients. a clinicopathologic evaluation. <i>Arthritis and Rheumatism</i> , 1993, 36, 1164-1174.	6.7	197
46	Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 110-116.	0.5	191
47	Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 396-401.	0.5	189
48	IgA vasculitis (Henoch-Schönlein purpura) in adults: Diagnostic and therapeutic aspects. <i>Autoimmunity Reviews</i> , 2015, 14, 579-585.	2.5	187
49	Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. <i>British Journal of Rheumatology</i> , 1997, 36, 1290-1297.	2.5	185
50	High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 564-567.	0.5	184
51	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1003-1010.	0.5	183
52	Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3788-3798.	6.7	181
53	Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. <i>Lupus</i> , 1998, 7, 238-258.	0.8	180
54	Treatment of polyarteritis nodosa and microscopic polyangiitis without poor prognosis factors: A prospective randomized study of one hundred twenty-four patients. <i>Arthritis and Rheumatism</i> , 2010, 62, 1186-1197.	6.7	179

#	ARTICLE	IF	CITATIONS
55	Polyarteritis Nodosa and Extrahepatic Manifestations of HBV Infection: The Case Against Autoimmune Intervention in Pathogenesis. <i>Journal of Autoimmunity</i> , 2001, 16, 269-274.	3.0	176
56	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013, 43, 60-69.	3.0	168
57	Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, openâ€“label study of twentyâ€“two patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 308-317.	6.7	163
58	Lack of Superiority of Steroids Plus Plasma Exchange to Steroids Alone in the Treatment of Polyarteritis Nodosa and Churg-Strauss Syndrome. <i>Arthritis and Rheumatism</i> , 1992, 35, 208-215.	6.7	159
59	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.5	159
60	Long-term follow-up of the <i>MAINTAIN</i> Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526-531.	0.5	157
61	Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. <i>Thorax</i> , 2005, 60, 765-772.	2.7	150
62	Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixtyâ€“Five Years or Older: Results of a Multicenter, Openâ€“Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamideâ€“Based Induction Therapy. <i>Arthritis and Rheumatology</i> , 2015, 67, 1117-1127.	2.9	150
63	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012, 51, 460-467.	0.9	147
64	New insights into the pathogenesis of systemic sclerosis. <i>Autoimmunity Reviews</i> , 2003, 2, 152-157.	2.5	141
65	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	2.5	140
66	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1150-1156.	0.5	139
67	Predicting mortality in systemic Wegener's granulomatosis: A survival analysis based on 93 patients. <i>Arthritis and Rheumatism</i> , 2004, 51, 83-91.	6.7	137
68	Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	3.0	136
69	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fiftyâ€“Seven Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 527-534.	2.9	136
70	Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1273-1279.	0.5	132
71	Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 658-663.	0.5	131
72	Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. <i>British Journal of Rheumatology</i> , 1996, 35, 958-964.	2.5	129

#	ARTICLE	IF	CITATIONS
73	Primary Angiitis of the Central Nervous System: Description of the First Fifty-two Adults Enrolled in the French Cohort of Patients With Primary Vasculitis of the Central Nervous System. <i>Arthritis and Rheumatology</i> , 2014, 66, 1315-1326.	2.9	129
74	Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schœnlein Purpura. <i>Kidney International</i> , 2010, 78, 495-502.	2.6	128
75	Prevalence of systemic sclerosis in a French multi-ethnic county. <i>British Journal of Rheumatology</i> , 2004, 43, 1129-1137.	2.5	126
76	Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. <i>European Respiratory Journal</i> , 2006, 28, 799-807.	3.1	123
77	Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 2004, 51, 482-487.	6.7	122
78	Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. <i>European Respiratory Review</i> , 2013, 22, 535-542.	3.0	120
79	Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. <i>Autoimmunity Reviews</i> , 2017, 16, 1036-1043.	2.5	120
80	The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. <i>Thorax</i> , 2008, 63, 677-682.	2.7	119
81	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2009, 136, 1211-1219.	0.4	117
82	Characteristics and Management of IgA Vasculitis (Henoch-Schœnlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. <i>Arthritis and Rheumatology</i> , 2017, 69, 1862-1870.	2.9	117
83	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors. <i>Arthritis and Rheumatology</i> , 2017, 69, 2175-2186.	2.9	117
84	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	2.0	116
85	Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. <i>The Cooperative Study Group for Polyarteritis Nodosa. Journal of Rheumatology</i> , 1991, 18, 567-74.	1.0	114
86	Microscopic polyangiitis and polyarteritis nodosa: How and when do they start?. <i>Arthritis and Rheumatism</i> , 2003, 49, 709-715.	6.7	113
87	Ophthalmologic Manifestations of Systemic Necrotizing Vasculitides at Diagnosis: A Retrospective Study of 1286 Patients and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 507-514.	1.6	112
88	Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. <i>Rheumatology</i> , 2014, 53, 532-539.	0.9	111
89	Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 334-337.	0.5	109
90	Microscopic polyangiitis: Clinical presentation. <i>Autoimmunity Reviews</i> , 2010, 9, 812-819.	2.5	109

#	ARTICLE	IF	CITATIONS
91	Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. <i>Rheumatology</i> , 2001, 40, 147-151.	0.9	108
92	Systemic necrotizing angiitis with asthma: Causes and precipitating factors in 43 cases. <i>Lung</i> , 1987, 165, 165-172.	1.4	107
93	Churg's "Strauss syndrome: evidence for disease subtypes?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 21-28.	2.0	103
94	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg's "Strauss). <i>European Respiratory Journal</i> , 2016, 48, 1429-1441.	3.1	102
95	Long-term Outcomes Among Participants in the WEGENT Trial of Remission Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	2.9	101
96	Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 404-407.	0.5	99
97	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. <i>Journal of Rheumatology</i> , 2008, 35, 1064-72.	1.0	99
98	Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. <i>British Journal of Rheumatology</i> , 2002, 41, 290-300.	2.5	92
99	Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2011, 50, 2214-2222.	0.9	91
100	Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. <i>European Respiratory Journal</i> , 2012, 39, 1405-1414.	3.1	90
101	A paradigm of diagnostic criteria for polyarteritis nodosa: Analysis of a series of 949 patients with vasculitides. <i>Arthritis and Rheumatism</i> , 2008, 58, 1528-1538.	6.7	89
102	Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. <i>Rheumatology</i> , 2015, 54, 424-432.	0.9	89
103	Protective effect of A/H1N1 vaccination in immune-mediated disease—a prospectively controlled vaccination study. <i>Rheumatology</i> , 2012, 51, 695-700.	0.9	86
104	European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSTRIAL (BMH-Cr93-1078). <i>Clinical and Experimental Immunology</i> , 1995, 101, 29-34.	1.1	85
105	Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg's "Strauss): Data on Seventeen Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 2274-2282.	2.9	84
106	Factors associated with <i>Pneumocystis carinii</i> pneumonia in Wegener's granulomatosis.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 991-994.	0.5	83
107	Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. <i>Journal of Rheumatology</i> , 1993, 20, 289-98.	1.0	83
108	Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1343-1346.	0.5	81

#	ARTICLE	IF	CITATIONS
109	Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. <i>British Journal of Dermatology</i> , 2008, 159, 615-620.	1.4	79
110	Scleroderma Renal Crisis. <i>Journal of Rheumatology</i> , 2014, 41, 1040-1048.	1.0	79
111	Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome—62 patients. <i>Journal of Rheumatology</i> , 1993, 20, 1345-9.	1.0	79
112	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 197-205.	2.5	77
113	Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis. <i>Journal of Rheumatology</i> , 2012, 39, 125-130.	1.0	75
114	Vasculitis: mechanisms involved and clinical manifestations. <i>Arthritis Research and Therapy</i> , 2007, 9, S9.	1.6	74
115	Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1770-1776.	0.5	72
116	FDG-PET/CT in patients with ANCA-associated vasculitis: Case-series and literature review. <i>Autoimmunity Reviews</i> , 2014, 13, 125-131.	2.5	71
117	Peripheral neuropathy in systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2005, 17, 41-48.	2.0	70
118	Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 963-969.	2.5	70
119	Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. <i>Autoimmunity Reviews</i> , 2014, 13, 313-318.	2.5	69
120	Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. <i>Arthritis and Rheumatism</i> , 2011, 63, 1435-1445.	6.7	68
121	Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases. <i>Arthritis and Rheumatism</i> , 2005, 52, 4028-4038.	6.7	67
122	Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. <i>Journal of Autoimmunity</i> , 2014, 50, 135-141.	3.0	67
123	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	0.9	67
124	Polyarteritis nodosa and parvovirus B19. <i>Lancet</i> , 1994, 344, 263-264.	6.3	65
125	Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. <i>British Journal of Rheumatology</i> , 2003, 42, 1183-1188.	2.5	62
126	Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. <i>Rheumatology</i> , 2011, 50, 953-961.	0.9	62

#	ARTICLE	IF	CITATIONS
127	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013, 42, 1317-1330.	0.8	62
128	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 141.	1.2	62
129	Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, S23-7.	0.4	61
130	Eosinophilic Granulomatosis with Polyangiitis (Churgâ€“Strauss). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 471-481.	0.8	59
131	Endothelin-1 expression in scleroderma renal crisisâ†. <i>Human Pathology</i> , 2011, 42, 95-102.	1.1	58
132	Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. <i>Rheumatology</i> , 2013, 52, 642-650.	0.9	57
133	Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitides: A French Nationwide Study of Ninetyâ€“Two Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 702-712.	2.9	57
134	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 498-503.	2.9	55
135	Systemic Vasculitis During the Course of Systemic Sclerosis. <i>Medicine (United States)</i> , 2013, 92, 1-9.	0.4	54
136	Kawasaki disease in adults: Observations in France and literature review. <i>Autoimmunity Reviews</i> , 2016, 15, 242-249.	2.5	54
137	Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2455-2463.	6.7	53
138	Vasculitides in the context of HIV infection. <i>Aids</i> , 2008, 22, S27-S33.	1.0	53
139	Severe bronchospasm associated with rituximab for refractory Churgâ€“Strauss syndrome. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 606-606.	0.5	53
140	Infections in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 19-31.	1.4	53
141	Tumor necrosis factor-alpha blockade and the risk of vasculitis. <i>Journal of Rheumatology</i> , 2004, 31, 1885-7.	1.0	53
142	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 1050-1059.	1.5	52
143	Cardiac involvement in small and medium-sized vessel vasculitides. <i>Lupus</i> , 2005, 14, 718-722.	0.8	50
144	Pulmonary arterial hypertension: an autoimmune disease?. <i>European Respiratory Journal</i> , 2005, 26, 986-988.	3.1	49

#	ARTICLE	IF	CITATIONS
145	Hypereosinophilic syndromes. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 863-882.	1.4	48
146	Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 945-953.	2.5	48
147	Increased risk of <i>Pneumocystis carinii</i> pneumonia in patients with Wegener's granulomatosis. <i>Clinical and Experimental Rheumatology</i> , 1993, 11, 615-21.	0.4	48
148	Churg-Strauss Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 535-545.	0.8	47
149	Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. <i>Current Opinion in Rheumatology</i> , 1995, 7, 20-4.	2.0	46
150	Symptomatic Urogenital Manifestations of Polyarteritis Nodosa and Churg-Strauss Angiitis: Analysis of 8 of 165 Patients. <i>Journal of Urology</i> , 1989, 142, 136-138.	0.2	45
151	Polyarteritis Nodosa and Churg-Strauss Angiitis. <i>Medicine (United States)</i> , 2002, 81, 27-40.	0.4	45
152	Indications of Plasma Exchanges for Systemic Vasculitides. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 155-160.	0.4	45
153	Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2125-2130.	0.5	45
154	Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. <i>Arthritis Research and Therapy</i> , 2011, 13, R107.	1.6	44
155	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune-Mediated Inflammatory Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1504-1514.	1.5	43
156	Treatment and Long-Term Outcomes of Primary Central Nervous System Vasculitis. <i>Stroke</i> , 2018, 49, 1946-1952.	1.0	43
157	Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. <i>Autoimmunity Reviews</i> , 2019, 18, 493-500.	2.5	43
158	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. <i>Journal of Autoimmunity</i> , 2020, 106, 102338.	3.0	43
159	Polyarteritis nodosa and microscopic polyangiitis. <i>Clinical and Experimental Immunology</i> , 1995, 101, 22-23.	1.1	42
160	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , 2014, 43, e345-e363.	0.8	42
161	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 108-114.	2.5	42
162	Churg-Strauss Syndrome: Clinical Symptoms, Complementary Investigations, Prognosis and Outcome, and Treatment. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 298-309.	0.8	41

#	ARTICLE	IF	CITATIONS
163	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 596-605.	0.5	41
164	Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.3	41
165	TREATMENT OF SYSTEMIC VASCULITIS WITH CYCLOPHOSPHAMIDE AND STEROIDS: DAILY ORAL LOW-DOSE CYCLOPHOSPHAMIDE ADMINISTRATION AFTER FAILURE OF A PULSE INTRAVENOUS HIGH-DOSE REGIMEN IN FOUR PATIENTS. <i>Rheumatology</i> , 1994, 33, 959-962.	0.9	40
166	Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients. <i>Rheumatology</i> , 2017, 56, 947-956.	0.9	40
167	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	2.5	40
168	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.2	39
169	Serum Eosinophil Cationic Protein: A Marker of Disease Activity in Churg-Strauss Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 392-399.	1.8	38
170	Infliximab in the treatment of posterior uveitis in Behçet's disease. <i>Presse Medicale</i> , 2005, 34, 916-918.	0.8	37
171	Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. <i>Autoimmunity Reviews</i> , 2015, 14, 774-780.	2.5	37
172	Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. <i>Drugs</i> , 2018, 78, 809-821.	4.9	36
173	Churg-Strauss Angiitis. <i>Chest</i> , 1991, 100, 1472-1473.	0.4	35
174	When Should Immunosuppressants Be Prescribed to Treat Systemic Vasculitides?. <i>Internal Medicine</i> , 2003, 42, 313-317.	0.3	35
175	Levamisole-induced vasculopathy: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 921-926.	1.6	35
176	Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. <i>Rheumatology</i> , 2019, 58, 401-409.	0.9	35
177	HIV-related vasculitis: clinical presentation and therapeutic approach on six patients. <i>Aids</i> , 1997, 11, 121-3.	1.0	35
178	Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S70-6.	0.4	35
179	Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. <i>British Journal of Rheumatology</i> , 1999, 38, 183-185.	2.5	34
180	IgM and IgG autoantibodies from microscopic polyangiitis patients but not those with other small- and medium-sized vessel vasculitides recognize multiple endothelial cell antigens. <i>Clinical Immunology</i> , 2003, 109, 165-178.	1.4	34

#	ARTICLE	IF	CITATIONS
181	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. <i>Journal of Autoimmunity</i> , 2015, 65, 49-55.	3.0	34
182	mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. <i>Rheumatology</i> , 2018, 57, 1011-1020.	0.9	33
183	Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. <i>Rheumatology</i> , 2019, 58, 2107-2116.	0.9	33
184	Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 98-104.	1.6	33
185	Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. <i>Autoimmunity Reviews</i> , 2017, 16, 1138-1146.	2.5	32
186	Polyarteritis Nodosa Neurologic Manifestations. <i>Neurologic Clinics</i> , 2019, 37, 345-357.	0.8	32
187	Adult primary angiitis of the central nervous system: isolated small-vessel vasculitis represents distinct disease pattern. <i>Rheumatology</i> , 2017, 56, kew434.	0.9	31
188	Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. <i>Journal of Hepatology</i> , 2000, 33, 677-683.	1.8	31
189	Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S83-9.	0.4	31
190	Classification and Management of Necrotising Vasculitides. <i>Drugs</i> , 1997, 53, 805-816.	4.9	30
191	Scleroderma Renal Crisis, Still a Life-Threatening Complication. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 249-258.	1.8	30
192	Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach. <i>Autoimmunity Reviews</i> , 2021, 20, 102707.	2.5	30
193	Circulating immune complexes in systemic necrotizing vasculitis of the polyarteritis nodosa group. Comparison of HBV-related polyarteritis nodosa and Churg Strauss angiitis. <i>Journal of Autoimmunity</i> , 1990, 3, 789-792.	3.0	29
194	Maintenance therapy is associated with better long-term outcomes in adult patients with primary angiitis of the central nervous system. <i>Rheumatology</i> , 2017, 56, 1684-1693.	0.9	29
195	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018, 57, 96-104.	1.0	29
196	L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Presse Medicale</i> , 2013, 42, 507-510.	0.8	28
197	Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. <i>Autoimmunity Reviews</i> , 2017, 16, 398-406.	2.5	28
198	Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. <i>Proteomics</i> , 2009, 9, 2253-2262.	1.3	27

#	ARTICLE	IF	CITATIONS
199	Regressing microaneurysms in 5 cases of hepatitis B virus related polyarteritis nodosa. <i>Journal of Rheumatology</i> , 1995, 22, 876-80.	1.0	27
200	Virus-induced Systemic Vasculitides: New Therapeutic Approaches. <i>Clinical and Developmental Immunology</i> , 2004, 11, 227-231.	3.3	26
201	Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. <i>Presse Medicale</i> , 2008, 37, 412-415.	0.8	26
202	The Advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade. <i>Journal of Clinical Immunology</i> , 2013, 33, 27-32.	2.0	26
203	Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S63-71.	0.4	26
204	Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: A systematic review and network meta-analysis. <i>Joint Bone Spine</i> , 2014, 81, 337-341.	0.8	25
205	Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: A proteomic approach. <i>Clinical Immunology</i> , 2014, 153, 123-135.	1.4	25
206	Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. <i>Journal of Autoimmunity</i> , 2020, 112, 102467.	3.0	25
207	Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, ß-interferon and lamivudine. <i>Journal of Hepatology</i> , 2000, 33, 677-683.	1.8	24
208	Scleroderma Renal Crisis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 475-488.	0.8	24
209	Therapeutic Strategies for Systemic Necrotizing Vasculitides. <i>Allergology International</i> , 2007, 56, 105-111.	1.4	23
210	Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1269-1270.	0.5	23
211	Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S77-82.	0.4	23
212	Updates for the treatment of EGPA. <i>Presse Medicale</i> , 2020, 49, 104036.	0.8	22
213	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	1.6	22
214	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021, 60, 4355-4360.	0.9	21
215	ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. <i>Presse Medicale</i> , 2020, 49, 104031.	0.8	21
216	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	0.9	20

#	ARTICLE	IF	CITATIONS
217	Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex. <i>Journal of Rheumatology</i> , 2001, 28, 631-3.	1.0	20
218	Successful treatment of thymoma-associated pure red cell aplasia with intravenous immunoglobulins. <i>European Journal of Haematology</i> , 2000, 65, 74-76.	1.1	19
219	Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit. <i>Journal of Rheumatology</i> , 2015, 42, 1406-1412.	1.0	19
220	Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. <i>Presse Medicale</i> , 2007, 36, 771-778.	0.8	18
221	Treatment of granulomatosis with polyangiitis (Wegener's). <i>Expert Review of Clinical Immunology</i> , 2015, 11, 339-348.	1.3	18
222	Antineutrophilic cytoplasmic antibody-associated vasculitis and malignant hemopathies, a retrospective study of 16 cases. <i>Joint Bone Spine</i> , 2017, 84, 51-57.	0.8	18
223	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Network Open</i> , 2022, 5, e2220925.	2.8	18
224	How can patient care be improved beyond medical treatment?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 337-344.	1.4	17
225	Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor β pathway in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2011, 13, R74.	1.6	17
226	Concordance of Time-of-Flight MRA and Digital Subtraction Angiography in Adult Primary Central Nervous System Vasculitis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1917-1922.	1.2	17
227	Indication for plasma exchange for systemic necrotizing vasculidities. <i>Transfusion and Apheresis Science</i> , 2007, 36, 179-185.	0.5	16
228	Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 404-406.	0.6	16
229	Cardiac magnetic resonance imaging in Churg-Strauss-syndrome. Impact of immunosuppressants on outcome assessed in a prospective study on 8 patients. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 8-13.	0.4	16
230	Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 904-5.	0.4	16
231	Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg's Strauss syndrome and Wegener's granulomatosis. <i>Journal of Autoimmunity</i> , 2005, 24, 169-179.	3.0	15
232	Therapeutic immunomodulation in systemic vasculitis: Taking stock. <i>Joint Bone Spine</i> , 2013, 80, 374-379.	0.8	15
233	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 681-688.	1.6	15
234	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 984-989.	2.5	15

#	ARTICLE	IF	CITATIONS
235	Rituximab treatment of ANCA-associated vasculitis. Expert Opinion on Biological Therapy, 2020, 20, 899-910.	1.4	15
236	Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clinical and Experimental Rheumatology, 2015, 33, S-77-83.	0.4	15
237	Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. Clinical and Experimental Rheumatology, 2013, 31, 71-80.	0.4	15
238	Vasculopathy and pulmonary arterial hypertension. Rheumatology, 2006, 48, iii54-iii57.	0.9	14
239	Esophageal involvement as an initial manifestation of Churg-Strauss syndrome. Presse Medicale, 2007, 36, 57-60.	0.8	14
240	Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients. Presse Medicale, 2013, 42, 679.	0.8	13
241	Vasculitis for the internist: focus on ANCA-associated vasculitis. Internal and Emergency Medicine, 2017, 12, 577-585.	1.0	13
242	Distal ischemia as the initial presentation of hypereosinophilic syndrome-related arterial involvement: A case study and literature review. Autoimmunity Reviews, 2019, 18, 828-830.	2.5	13
243	Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. Rheumatology, 2020, 59, 2250-2257.	0.9	13
244	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Annals of Internal Medicine, 2020, 173, 948.	2.0	13
245	Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis. Clinical and Experimental Rheumatology, 2010, 28, 90-2.	0.4	13
246	S3. Rituximab for ANCA-associated vasculitides: The French experience. Presse Medicale, 2013, 42, 534-536.	0.8	12
247	Mepolizumab for eosinophilic granulomatosis with polyangiitis. Nature Reviews Rheumatology, 2017, 13, 518-519.	3.5	12
248	Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Annales De Médecine Interne, 1996, 147, 81-6.	0.2	12
249	Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis. Fundamental and Clinical Pharmacology, 2000, 14, 415-421.	1.0	11
250	Reintroduction of vitamin B ₁₂ in 2 patients with prior B ₁₂ -induced anaphylaxis. European Journal of Haematology, 1998, 60, 269-270.	1.1	11
251	Eosinophilic granulomatosis with polyangiitis (formerly Churg's "Strauss syndrome): where are we now?. European Respiratory Journal, 2015, 46, 1255-1258.	3.1	11
252	Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study. Rheumatology, 2022, 61, 775-780.	0.9	11

#	ARTICLE	IF	CITATIONS
253	Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churgâ€“Strauss). <i>Rheumatology</i> , 2022, 61, 1175-1184.	0.9	11
254	Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. <i>Annales De MÃ©decine Interne</i> , 1992, 143 Suppl 1, 63-74.	0.2	11
255	Management of virus-induced systemic vasculitides. <i>Current Rheumatology Reports</i> , 2002, 4, 60-66.	2.1	10
256	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	1.0	10
257	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 436-441.	1.6	10
258	Human immunodeficiency virus-related vasculitis. Clinical presentation of and therapeutic approach to eight cases. <i>Annales De MÃ©decine Interne</i> , 1998, 149, 398-405.	0.2	10
259	A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 155-160.	0.4	10
260	Advances in the Treatments of Systemic Vasculitides. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 72-78.	2.9	9
261	Treatment of Severe and/or Refractory ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2014, 16, 430.	2.1	9
262	Conventional and biological immunosuppressants in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 94-111.	1.4	9
263	Impact of aging on phenotype and prognosis in IgA vasculitis. <i>Rheumatology</i> , 2021, 60, 4245-4251.	0.9	9
264	Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides. <i>Journal of Clinical Medicine</i> , 2021, 10, 2299.	1.0	9
265	Delayed relapse of Churg-Strauss syndrome manifesting as colon ulcers with mucosal granulomas: 3 cases. <i>Journal of Rheumatology</i> , 2002, 29, 388-91.	1.0	9
266	Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 40-46.	0.4	9
267	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	1.8	9
268	Progress in systemic sclerosis: a 10-year perspective. <i>Rheumatology</i> , 2006, 48, iii1-iii2.	0.9	8
269	Clinical trials on systemic necrotizing vasculitides. <i>Presse Medicale</i> , 2010, 39, 653-659.	0.8	8
270	No evident association of nasal carriage of <i>Staphylococcus aureus</i> or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. <i>Rheumatology</i> , 2020, 59, 77-83.	0.9	8

#	ARTICLE	IF	CITATIONS
271	Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. <i>Journal of Internal Medicine</i> , 2021, , .	2.7	8
272	Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S89-92.	0.4	8
273	Pharmacoeconomics of immunoglobulins and indications for their use. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, S53-S55.	1.1	7
274	Treating giant-cell arteritis: is IL-6 the cytokine to target?. <i>Lancet, The</i> , 2016, 387, 1882-1883.	6.3	7
275	Risk of malignancy in patients treated for systemic necrotising vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 431-433.	0.5	7
276	Treatment of systemic necrotizing vasculitides: The 40-year experience of the French Vasculitis Study Group. <i>Presse Medicale</i> , 2020, 49, 104034.	0.8	7
277	IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-Î± blockers. <i>Rheumatology</i> , 2022, 61, 1957-1965.	0.9	7
278	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 176-184.	0.4	7
279	Rituximab as first-line therapy for acquired haemophilia <sc>A</sc>: a single-centre 10-year experience. <i>Haemophilia</i> , 2016, 22, e338-41.	1.0	6
280	Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?. <i>Rheumatology</i> , 2022, 61, 4056-4064.	0.9	6
281	Bladder Neuropathy and Gastric Paralysis in Polyarteritis Nodosa Associated with Hepatitis B Virus. <i>Scandinavian Journal of Rheumatology</i> , 1990, 19, 442-443.	0.6	5
282	Definition for eosinophilia in Churg-Strauss syndrome. <i>Presse Medicale</i> , 2011, 40, 224-225.	0.8	5
283	Atypical Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Medicine</i> , 2015, 128, e47-e49.	0.6	5
284	Comment on: First report of <i>FIP1L1-PDGFRÎ±</i>-positive eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2016, 55, 384-385.	0.9	5
285	305. â€fREDUCING THE NUMBER OF RITUXIMAB INFUSIONS AT ONSET OF MAINTENANCE THERAPY FOR ANCA-ASSOCIATED VASCULITIDES: RESULTS OF A POST HOC ANALYSIS FROM A RANDOMIZEDâ€“CONTROLLED TRIAL. <i>Rheumatology</i> , 2019, 58, .	0.9	5
286	Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis. <i>Rheumatology</i> , 2022, 61, 2619-2624.	0.9	5
287	Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S121-8.	0.4	5
288	Cutaneous granulomatous vasculitis and extravascular granulomas. <i>Expert Review of Dermatology</i> , 2006, 1, 315-326.	0.3	4

#	ARTICLE	IF	CITATIONS
289	Indications for biotherapy in systemic vasculitides. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 85-95.	2.9	4
290	Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2021, , .	0.9	4
291	Treatment of ANCA-Associated Vasculitides. , 2016, , 425-431.		4
292	Indications of plasma exchanges in 2000. <i>Annales De MÃ©decine Interne</i> , 2000, 151, 123-35.	0.2	4
293	Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 152-159.	0.4	4
294	Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population. <i>Rheumatology</i> , 2016, 56, kew423.	0.9	3
295	New therapeutic approaches for ANCA-associated vasculitides. <i>Presse Medicale</i> , 2016, 45, e171-e178.	0.8	3
296	Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-Î± antagonists in France? The CORPUS cohort study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 602-10.	0.4	3
297	A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 155-160.	0.4	3
298	Treatment of primary systemic necrotizing vasculitides: the role of biotherapies. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 622-627.	0.7	2
299	L51. From immunosuppression to selective treatments: The benefitâ€“risk ratio. <i>Presse Medicale</i> , 2013, 42, 641-643.	0.8	2
300	Response to: â€“Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss; EGPA): to use or not to use?â€™ by Moiseev and Novikov. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e13-e13.	0.5	2
301	Maintenance of Remission in antineutrophil cytoplasm antibodyâ€“associated vasculitides. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 100-104.	0.9	2
302	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. <i>Autoimmunity Reviews</i> , 2021, 20, 102874.	2.5	2
303	Polyarteritis Nodosa and Churg-Strauss Syndrome an Internistâ€™s View. <i>Advances in Experimental Medicine and Biology</i> , 1993, 336, 173-184.	0.8	2
304	Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	2
305	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. <i>Presse Medicale</i> , 2022, 51, 104107.	0.8	2
306	Tobacco differentially affects the clinical-biological phenotypes of ANCA-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-116-21.	0.4	2

#	ARTICLE	IF	CITATIONS
307	Maintenance treatment of ANCA-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 199-201.	0.4	2
308	Abdominal adipose tissue predicts major cardiovascular events in systemic necrotising vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 130-136.	0.4	2
309	Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. <i>Rheumatology</i> , 2022, 62, 341-346.	0.9	2
310	Infliximab reverses progressive deafness. <i>Presse Medicale</i> , 2015, 44, 675-677.	0.8	1
311	VAC-04 - Echec de la vaccination antipneumococcique en phase d'attaque du traitement des vascularites à ANCA : l'étude pneumovas pilote 1. <i>Médecine Et Maladies Infectieuses</i> , 2016, 46, 111.	5.1	1
312	Polyarteritis Nodosa. , 2017, , 419-427.		1
313	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 151-152.	2.9	1
314	Response to: "MAINRITSAN2-the future", with some doubts! by Chattopadhyay et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e140-e140.	0.5	1
315	Treatment of ANCA-Associated Vasculitides. <i>Rare Diseases of the Immune System</i> , 2020, , 313-328.	0.1	1
316	Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss). <i>Rare Diseases of the Immune System</i> , 2020, , 77-95.	0.1	1
317	Antiphospholipid syndrome: the burden of inadequate anticoagulation management. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
318	World Apheresis Association President's Welcome and Invitation. <i>Therapeutic Apheresis and Dialysis</i> , 2005, 9, 105-105.	0.4	0
319	Skin Involvement in Small, Medium-sized Vessel and Granulomatous Vasculitides. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006, 5, 275-294.	0.1	0
320	Imaging Features of Granulomatosis with Polyangiitis (Wegener's). <i>Medical Radiology</i> , 2011, , 259-278.	0.0	0
321	Lung Vasculitis and Alveolar Hemorrhage. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 243-244.	0.8	0
322	ABO438...Vasculitis associated with large granular lymphocyte leukemia : presentation and treatment outcomes. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A922.3-A922.	0.5	0
323	Vasculitis research: Don't slow down and plan for a life-time commitment. <i>Presse Medicale</i> , 2015, 44, e221-e222.	0.8	0
324	Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): A Clinical and Therapeutic Approach. , 2015, , 113-125.		0

#	ARTICLE	IF	CITATIONS
325	Pharmacological approach to treating eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss). Expert Opinion on Orphan Drugs, 2015, 3, 505-515.	0.5	0
326	SAT0351â€“Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study OF34 Patients. Annals of the Rheumatic Diseases, 2016, 75, 794.1-794.	0.5	0
327	Innovations in autoimmune diseases. Presse Medicale, 2016, 45, e157-e158.	0.8	0
328	Clasificaci3n de las vasculitis sist3micas. EMC - Tratado De Medicina, 2017, 21, 1-5.	0.0	0
329	Treatment of Pulmonary Vasculitis. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 504-510.	0.8	0
330	Pulmonary Vasculitis and Alveolar Hemorrhage. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 411-412.	0.8	0
331	Response to: â€“Not all drugs (and routes) are same' by Zanwar and Gandhi. Annals of the Rheumatic Diseases, 2019, 78, e75-e75.	0.5	0
332	Therapeutic plasma exchanges: Still an effective therapeutic intervention. Presse Medicale, 2019, 48, 317-318.	0.8	0
333	Discussion suite � la communication�: ��Maintien de la r�mission des vascularites associ�es aux anticorps anticytoplasme des polynucl�aires neutrophiles (ANCA). Quel traitement d�entretien��. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 59.	0.0	0
334	A new challenge for La Presse M�dicale. Presse Medicale, 2020, 49, 104030.	0.8	0
335	Principales vasculitis necrosantes. EMC - Aparato Locomotor, 2020, 53, 1-24.	0.1	0
336	Les atteintes pulmonaires de la scl�rodermie. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 79-92.	0.0	0
337	Severe Polyarteritis Nodosa. , 2011, , 119-131.		0
338	Vascularites Syst�miques. , 2011, , 355-364.		0
339	OP0031â€“AN INCREASE IN SERUM CALPROTECTIN LEVEL IN ANCA-ASSOCIATED VASCULITIDES PATIENTS DURING MAINTENANCE THERAPY IS ASSOCIATED WITH MORE RELAPSE AND ACCELERATED RENAL FUNCTION DECLINE. Annals of the Rheumatic Diseases, 2020, 79, 22.3-22.	0.5	0
340	AB0467â€“REMISSION AND LOW DISEASE ACTIVITY STATE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS: PREVALENCE AND IMPACT ON DAMAGE ACCRUAL. Annals of the Rheumatic Diseases, 2020, 79, 1531.1-1532.	0.5	0
341	Systemic sclerosis: What does the future hold?. Presse Medicale, 2021, 50, 104106.	0.8	0
342	Immunosuppressants in systemic necrotizing vasculitides. Israel Medical Association Journal, 2001, 3, 749-54.	0.1	0

#	ARTICLE	IF	CITATIONS
343	Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides. Israel Medical Association Journal, 2008, 10, 89-91.	0.1	0
344	Optimising ANCA-associated vasculitis management and infectious risks during the COVID-19 pandemic. Clinical and Experimental Rheumatology, 2022, 40, 688-690.	0.4	0